Amylin Pharmaceuticals, Inc. (AMLN) Posts Q3 Loss of $0.07, Sales Fall Short
Tweet
Share
E-mailGet Alerts AMLN Hot Sheet
Price: $30.98 --0%
Financial Fact:
Total costs and expenses: 208.02M
Today's EPS Names:
OFLX, VAXX, NMRD, More
Financial Fact:
Total costs and expenses: 208.02M
Today's EPS Names:
OFLX, VAXX, NMRD, More
Join SI Premium – FREE
Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN) reported Q3 EPS of ($0.07), $0.08 better than the analyst estimate of ($0.15). Revenue for the quarter came in at $155.1 million versus the consensus estimate of $166.39 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ondas Holdings Inc. (ONDS) Misses Q2 EPS by 9c
- Cellebrite DI Ltd. (CLBT) Tops Q2 EPS by 4c ; Offers Guidance
- MeiraGTx Holdings plc (MGTX) Tops Q2 EPS by 202c
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
